Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2020 April;72(2) > Minerva Urologica e Nefrologica 2020 April;72(2):214-22

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Urologica e Nefrologica 2020 April;72(2):214-22

DOI: 10.23736/S0393-2249.19.03377-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression

Giuseppe PALERMO 1 , Pierfrancesco BASSI 1, Marco RACIOPPI 1, Salvatore M. RECUPERO 1, Emilio SACCO 1, Marco CAMPETELLA 1, Giulia CANU 2, Francesco PINTO 1

1 Department of Urology, A. Gemelli University Polyclinic, IRCCS and Foundation, Rome, Italy; 2 Department of Biochemistry, A. Gemelli University Polyclinic, IRCCS and Foundation, Rome, Italy



BACKGROUND: Circulating tumor cells (CTCs) represent a prerequisite for the formation of metastases. The aim of the study was to identify the role of CTCs as a biological marker of aggressiveness of prostate cancer and verify the expression of molecular markers predictive of response to different therapeutic approaches.
METHODS: Prospective, single-arm, non-randomized trial. Twenty-four patients with prostate cancer were enrolled into two groups: group 1 (N.=11) with localized prostate cancer treated with radical prostatectomy; group 2 (N.=13) with metastatic disease. We performed, dosage of blood PSA and testosterone, detection of EGFR, PSMA, PSA and Androgen Receptor (AR) expression on CTC during pre-treatment and follow-up at 1, 3, 9 and 18 months.
RESULTS: A total of 65 blood samples were evaluated. In group 1, pre-treatment sampling was negative for the expression of markers on CTC in 90% of the patients while group 2 pre-treatment sampling was positive for the expression of at least one biomarker in seven of 13 patients (54%). After treatment, four patients in group 2 experienced a reduced expression of the markers on CTC, however, in one case there was a new increase of PSA and PSMA at 3 months. One patient had a positivity of AR at 3 months.
CONCLUSIONS: The expression of PSA, PSMA, EGFR and AR on CTCs appears to be absent in the pre-treatment samplings in cases of localized prostate cancer. The same markers are hyper-expressed before treatment mostly in metastatic prostate cancer and can relate with early biochemical relapse.


KEY WORDS: Circulating neoplastic cells; Prostatic neoplasms; Biomarkers

top of page